Industry News
Biotechnology Industry News
Aspen Neuroscience’s cash…
Aspen Neuroscience’s cash reserves have been fertilized with a $115 million series C fundraising that will enrich the biotech’s ongoing trial of a regenerative cell therapy for Parkinson’s disease.
GSK has picked a novel protein…
GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal with Flagship Pioneering.
Merck KGaA has become the latest…
Merck KGaA has become the latest Big Pharma to tap the drug discovery expertise of Flagship Pioneering’s Valo Health. The German drugmaker has inked a deal to harness Valo’s reams of human biology data to
After laying off 80% of staffers…
After laying off 80% of staffers this spring, Tempest Therapeutics is acquiring several CAR-T programs from Factor Bioscience and bringing the latter’s CEO on board to helm the company.
Korea’s Celltrion is continuing…
Korea’s Celltrion is continuing to move beyond biosmilars, this time securing the option to use TriOar’s antibody platform in a deal potentially worth more than $350 million.
Merck & Co. has reported…
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval molecule as a new anchor treatment for the infectious disease.
CEO Paul Stoffels has left, and…
CEO Paul Stoffels has left, and his cell therapy strategy has been scrapped. So what happened to Galapagos?
GSK has paid $50 million upfront…
GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.
As the biopharma world…
As the biopharma world predominantly zeroes in on late-stage assets, Eli Lilly is prioritizing early science with the opening of a new Gateway Labs site, this time in Philadelphia.
Clinical trials succeed or stall…
Clinical trials succeed or stall based on one factor that’s easy to overlook: how well they fit into patients’ lives. The science of the trial may be sound and the protocol may be innovative, but
On its face, there wasn’t much…
On its face, there wasn’t much notable about Biogen’s May 2024 acquisition of Human Immunology Biosciences (HI-Bio). A $1.15 billion upfront payment to secure a phase 3-ready monoclonal antibody is chump change in the broader
Vanda Pharmaceuticals’ expansion…
Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. With the trial linking tradipitant to reduced nausea and vomiting in Wegovy patients, the biotech is gearing up to start a phase
This year saw attendance jump…
This year saw attendance jump again, with an estimated 4,500 people from 50 countries and across 950 healthcare companies set to show up.
Roche has reported another phase 3…
Roche has reported another phase 3 win for its oral selective estrogen receptor degrader. Success at a planned interim analysis positions giredestrant for use in the adjuvant setting, setting the Swiss drugmaker up to target
When Tim Hunt was invited to a…
When Tim Hunt was invited to a meeting with Robert F. Kennedy Jr. in early March, the Department of Health and Human Services secretary had only been sworn in a few weeks earlier.
Single-use technologies (SUT) are…
Single-use technologies (SUT) are well-suited for modular production environments and represent a valuable solution in today’s ever-evolving biologics development landscape.
Genmab has shed another…
Genmab has shed another antibody-drug conjugate from its April 2024 acquisition of ProfoundBio. The Danish pharma has dropped development of GEN1160, a company spokesperson confirmed to Fierce Biotech, halting a phase 1/2 trial of the
After laying off most of its staff…
After laying off most of its staff and partnering away its phase 3 cancer asset earlier this year, precision oncology outfit Repare Therapeutics has agreed to be acquired by nonprofit biotech XenoTherapeutics.
Bayer has built a home for Chinese…
Bayer has built a home for Chinese biopharma companies. Located in Beijing, the Bayer E-Town Open Innovation Center will incubate local biotechs starting with Suzhou Puhe BioPharma and Beijing Youngen Technology.
At the center of the acquisition…
At the center of the acquisition is Halda’s “hold and kill” bifunctional small molecule platform and a lead candidate in prostate cancer.